The promise of telesurgery in oncology The Lancet Oncology ++ ++...

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial Hua Zhong, MDa,* ∙ Jing Wang, MMb,* ∙ Runxiang Yang, MMc,* ∙ Yongzhong Luo, BMd,* ∙ Wei Zuo, MMe,* ∙ Wei Zhang, MDa,* ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00049-5/abstract?dgcid=raven_jbs_etoc_feature_lanonc A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR) Emily Alger, BSc MMathStata ∙ Antoine Regnault, PhDb ∙ Amylou C Dueck, PhDc ∙ Madeline Pe, PhDd ∙ Michael J Grayling, PhDe ∙ Melanie J Calvert, PhDf,g,h,i,j,k ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00018-5/abstract?dgcid=raven_jbs_etoc_feature_lanonc The promise of telesurgery in oncology The Lancet Oncology https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00134-8/fulltext?dgcid=raven_jbs_etoc_email Apr 2026 Volume 27Number 4p393-526, e170-e231 https://www.thelancet.com/journals/lanonc/issue/vol27no4/PIIS1470-2045(26)X2003-4